Reference:
Livingston, E. H., Malani, P. N., & Creech, C. B. (2021). The Johnson & Johnson vaccine for COVID-19. JAMA Patient Page. https://doi.org/10.1001/jama.2021.2927
Summary:
The Johnson & Johnson COVID-19 vaccine employs a unique approach using a modified adenovirus to induce an immune response without causing infection. Unlike mRNA vaccines from Pfizer and Moderna, which require ultracold storage and prompt cells to produce viral proteins, the Johnson & Johnson vaccine utilises stable DNA that does not replicate. Initial studies indicated that a single dose is 66% effective against moderate to severe COVID-19 and 100% effective at preventing hospitalisation and death. Side effects were comparable to other vaccines, with no severe allergic reactions reported. The vaccine is currently under review for Emergency Use Authorization by the US Food and Drug Administration. This vaccine’s easier storage and distribution make it a significant option in the fight against COVID-19.